PLRX — Pliant Therapeutics Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$1.24
Market Cap$74.3M
Float60.2M
Shares Outstanding61.9M
Price/Sales (TTM)3,071.82
vs. Analyst Target+115.1% to analyst PT
Dividend RateNone
Analyst Target Price$2.67 (13 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $41.8M -$39.7M $41.8M -$40.3M
2021 $7.6M -$17.9M $7.6M -$18.5M
2022 $9.7M -$123M $9.7M -$119M
2023 $1.6M -$161M $1.6M -$158M
2024 N/A -$210M -$2.1M -$205M
2025 N/A -$149M -$1.7M -$148M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$43.3M
Sep 2025 N/A -$26.3M
Dec 2025 N/A -$23.6M
Mar 2026 N/A -$20.0M

Ownership & Float

Insider Ownership2.3%
Institutional Ownership81.9%
Short Float5.7%
% of All Funds Holding1.01%
Number of Funds Holding83

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$1.24Near-term / short-term trend
Weekly40-Week SMA$1.37Medium-term trend
Weekly80-Week SMA$3.11Cyclical trend (business cycle)
Weekly200-Week SMA$12.18Secular trend (multi-year)
Monthly10-Month SMA$1.39Near-term monthly trend
Monthly20-Month SMA$3.80Medium-term monthly trend
Monthly40-Month SMA$10.58Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$1.50 resistance 1.41x 4 months ago
$3.10 resistance 2.96x 13 months ago
$10.50 resistance 4.53x 14 months ago

Historical Earnings Reactions (25 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.92% 0.48% 60.00% 10.00% -7.14%
1 Day 0.87% -1.19% 44.00% 11.59% -8.68%
1 Week -1.89% -3.05% 28.00% 13.41% -18.17%
2 Weeks -2.79% -7.61% 33.33% 26.30% -20.98%
1 Month -1.91% -3.67% 37.50% 55.61% -26.18%

Next earnings: July 30, 2026 (63 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.06% 49.6% 280
Tuesday 0.30% 50.2% 311
Wednesday 0.02% 45.8% 308
Thursday -0.04% 50.8% 301
Friday -0.37% 44.5% 301

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 81.9%

Insider Transactions — Smart Summary

Total insider ownership: 2.3%

12-Month Insider Activity Summary

Total Filings4
Net Value-$163,619.84
Net Shares Change-127,828
% of Float-0.2%
C-Suite Filings4
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
Coulie Bernard President and CEO -$114,400 1 N/A
Cummings Keith Lamont Chief Financial Officer -$30,722.56 1 N/A
Cheung Lily Chief Human Resource Officer -$9,643.52 1 N/A
Kuo Minnie Chief Operating Officer -$8,853.76 1 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-01-22 – 2026-01-22 4 4 -$163,619.84 4 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-01-22 Kuo Minnie Chief Operating Officer -$8,853.76 Transaction at $1.28, now -3.1%
2026-01-22 Cheung Lily Chief Human Resource Officer -$9,643.52 Transaction at $1.28, now -3.1%
2026-01-22 Cummings Keith Lamont Chief Financial Officer -$30,722.56 Transaction at $1.28, now -3.1%
2026-01-22 Coulie Bernard President and CEO -$114,400 Transaction at $1.28, now -3.1%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Pliant Therapeutics Inc (PLRX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for PLRX on Trend Edge →